解剖性与非解剖性肝切除治疗HCC对患者预后影响的RCT研究（中期总结）
|
摘要
一、背景与目的
对于早期HCC的治疗,目前学术界公认根治性切除是其最佳选择,而根治性切除术的术式有两种:解剖性肝切除术和非解剖性肝切除术。解剖性肝切除术是指:按照肝脏Couinaud分段进行肝切除术,包括单肝段切除及多肝段切除;解剖性肝切除术一般不需要Pringle法阻断第一肝门,关键是解剖出进入肝段的肝蒂和出肝静脉,分别予以结扎然后切除肝段。而非解剖性肝切除术定义为:完整切除肿瘤不考虑肝内解剖,一般要求切缘(RM)至少1.0cm。非解剖性肝切除术一般需要Pringle法阻断第一肝门或者半肝阻断,也可以不阻断第一肝门。目前国内外关于HCC手术方式对预后影响仍无定论。从循证医学的标准界定已经发表的国内外文献临床证据级别是B级或C级,未发现A级的临床证据。为了研究术式对HCC预后的影响,最佳的方法是应用临床随机对照研究(RCT),比较解剖性肝切除与非解剖性肝切除哪种术式更能减少术后复发,提高HCC术后无瘤生存率和累积生存率,从而为HCC根治性切除术的术式选择提供A级的证据。
大病理切片可以清楚的显示瘤体结构、交界区结构和“正常组织”区的连续过程。用于研究微转移的分布、数目、距离瘤体的距离等,较普通的病理切片有明显的优点。本研究沿在肝内门静脉血流方向的瘤体最大直径所在切面切开标本,行大病理切片检查,研究HCC微转移灶的数目、类型和转移距离及癌细胞Edmondson分级,为术式的选择提供病理学的证据。
血源性转移是HCC转移复发的主要方式。目前AFP mRNA被认为是比较有价值的循环HCC细胞标志物。实时荧光定量RT-PCR技术以其高效性、高特异性、高敏感性及计量准确等优点,成为目前检测CTCs的理想工具。手术可以刺激HCC细胞入外周血循环,因此收集HCC患者手术前后外周静脉血,提取外周血单核细胞(PBMCs,包含CTCs),采用实时荧光定量RT-PCR技术,检测外周血AFP mRNA手术前后的变化,估计两种术式外周血中CTCs数量变化是否有差异,为术式的选择提供细胞学的证据。
二、方法与结果
1.根据术前制定的患者纳入和排除标准,按照随机化的要求,每一个入组的HCC患者行相应的肝脏根治性切除术,收集临床、手术、病理资料,每2月随访1次,测定肝功能、血AFP和肝脏超声检查,每6个月检查胸片1次,怀疑复发时行肝脏或肺部CT检查。根据制定的判断复发标准界定有无复发,记录是否生存。结合随访信息,分析术式不同,术后复发率、术后死亡率、手术并发症的发生率是否不同;并采用Kaplan-Meier法生存分析,Log-rank法检验两组之间的术后早期复发率、术后早期无瘤生存率、术后早期累积生存率的生存曲线总体水平有无差异。本研究还分析了与预后有关的其他因素。
本研究自2006年1月1日起到2007年6月30日止,共纳入就诊于重庆西南医院肝胆外科研究所符合要求病例133例,其中解剖性肝切除67例,非解剖性肝切除66例。随访截至到2008年3月31日,中位随访时间是19个月(8～27个月),其中失访3例。两组的性别、年龄、HBV感染、Child-Pugh分级、ICGR-15、血AFP、术前肝功能、肿瘤直径、肿瘤包膜、肿瘤数目、HCC分级、肝硬化、TNM分级等一般情况和病理检查结果无统计学差异,说明两组具有可比性。术后分析的有关变量包括:两组手术切缘、手术出血量、围手术期输血量、术后肝功能、手术时间、住院时间、手术并发症、复发率、死亡率、无瘤生存和累积生存。解剖组术中出血量明显低于非解剖组,分别是(744.8±539.0)ml和(952.3±634.1)ml(p=0.044);两组围手术期输血量的中位数分别是0(0-5100)ml和600(0-4660)ml,解剖组明显低于非解剖组(p=0.035)。术后1天和5天的血ALT和TBIL值,解剖组也明显低于非解剖组。每组各有1例患者死于手术并发症。两组术后共46(34.6%, 46/133)人发生手术并发症,共发生57人次,其中解剖组19(28.4%, 19/67)人共21人次;非解剖组27(40.9%, 27/66)人共36人次。发生人数比例经过X2检验,两组无统计学差异(X~2=1.658, p=0.198);但发生人次比例经过X2检验,两组有明显统计学差异(X~2=6.045, p=0.014),说明解剖性肝切除术更能减少手术并发症的发生。两组共有43例发生复发或转移,占32.3%(43/133),其中肝内复发33例,占24.8%(33/133);肺部、椎骨或后腹膜等肝外转移10例占7.5%(10/133)。解剖组复发转移15例,占本组的22.4%(15/67);而非解剖组复发转移28例,占本组的42.4%(28/66),经X2检验,有明显统计学差异(X2=5.219,p=0.022)。共死亡25人,占18.8%(25/133),包括解剖组1例围手术期死于肝功能衰竭,非解剖组1例围手术期死于上消化道大出血。解剖组死亡10例,占本组的14.9%(10/67);而非解剖组死亡15例,占本组的22.7%(15/66),经X~2检验,无统计学差异(X2=0.864, p=0.353)。Kaplan-Meier法分析解剖组和非解剖组术后1年累积复发率是分别22.9%和41.8%,Log-rank法检验两组之间生存曲线总体水平有显著性差异(X2=5.614, p=0.018);解剖组和非解剖组术后1年无瘤生存率分别是75.5%和48.2%,总体水平有显著性差异(X2=8.601, p=0.003);解剖组和非解剖组术后1年累积生存率分别是86.8%和78.6%,总体水平无显著性差异(X~2=1.184, p=0.277)。结合单因素分析结果,COX回归模型多因素分析表明:HCC术后复发与手术方式、微转移、失血量、术前外周血AFP mRNA和肿瘤直径统计学明显相关。结合单因素分析结果,COX回归模型多因素分析表明:HCC术后早期无瘤生存率与手术方式、微转移和肿瘤边界是否清楚等3因素统计学明显相关。
2.观察并记录HCC切除标本肿瘤边界是否清楚、有无肿瘤包膜、有无肉眼转移灶,测量肿瘤直径、切缘距离、标本长度,标本固定后做成大病理切片,光学显微镜观察微转移数目、类型、测定微转移的距离及肿瘤细胞分级。运用组织等比回缩规律,换算出新鲜活体标本的微转移距离。本研究微转移分为两种:微癌栓和微卫星灶。本研究133例患者都进行了大病理切片检查。54.9% (73/133)患者的标本中发现微转移灶。在73例大标本肿瘤外肝组织内共检出了136个微转移:其中13.2%(18/136)为微卫星灶,86.8%(118/136)为微癌栓。在这136个微转移中,61.0%(83/136)为门静脉癌栓,15.4%(21/136)为肝静脉癌栓,还有10.3%(14/136)的癌栓难以分辨是门静脉还是肝静脉。肿瘤扩散距离的中位数是3.6mm,范围是1.1mm～20.2mm。肝内有无微转移与肿瘤大小、包膜完整性、TNM分期、癌细胞分化程度的相关性有统计学意义;与血清AFP浓度、肿瘤数目的相关性无统计学意义。解剖组共有39例(58.2%)患者发现微转移,共发现微转移灶78个,其中门静脉癌栓51个,肝静脉癌栓9个,其他癌栓8个,卫星灶10个。非解剖组共有34(51.5%)例患者发现微转移,共发现微转移灶58个,其中门静脉癌栓32个,肝静脉癌栓12个,其他癌栓6个,卫星灶8个。两组发现微转移病例数经X2检验无统计学差异(X~2=0.935,p=0.334)。两组微转移总数和门静脉癌栓数经过Mann-Whitney U检验有统计学差异(p=0.043和p=0.000)。Kaplan-Meier法分析无微转移组和有微转移组术后1年复发率是分别19.7%和43.1%,Log-rank法检验两组之间生存曲线总体水平有显著性差异(X~2=8.037, p=0.005);无微转移组和有微转移组术后1年无瘤生存率分别是76.0%和49.4%,总体水平有显著性差异(X~2=10.996,p=0.001);无微转移组和有微转移组术后1年累积生存率分别是88.5%和78.3%,总体水平有显著性差异(X~2=4.579, p=0.032)。
3.分别在术前和术后抽取133患者的5ml外周静脉血,肝素抗凝,收集PBMCs(包含CTCs),提取PBMCc的总RNA,利用实时荧光定量RT-PCR技术,检测外周血AFP mRNA在手术前后的变化。我们还检测了8例肝硬化、4例肝增生、8例肝血管瘤和10例健康志愿者外周血AFP mRNA的含量作为对照。研究表明实时荧光定量RT-PCR检测外周血微转移癌细胞的敏感性可以达1/10~6-10~7。HCC组的外周血AFP mRNA相对表达量中位数是3.97×10~(-3)(9.1×10~(-7)～6.52×10~(-1)),明显高于肝硬化组、肝血管瘤组、肝脏增生组和健康对照组,差异有统计学意义(p=0.000)。HCC患者术后外周血AFP mRNA相对表达量的中位数是:1.673×10~(-2)(范围8.0×10~(-7)～5.170×10~(-1)),明显高于术前3.974×10~(-3)(范围9.0×10~(-7)～6.518×10~(-1))的水平(p=0.000)。经过统计学分析,两组手术前外周血AFP mRNA水平无统计学差异。非解剖组术后外周血AFP mRNA水平的中位数是2.24×10~(-2) (范围4.3×10~(-7)～5.10×10~(-1)),而解剖组是1.35×10~(-2) (范围1.32×10~(-6)～4.17×10~(-1)),非解剖组高于解剖组,但是无统计学差异(p=0.092)。HCC组术前AFP mRNA水平相对表达量与TNM分期、微转移、肿瘤大小有明显统计学意义(p=0.003, p=0.002和p=0.000),与肿瘤数目、包膜完整性均、癌细胞分化程度与血清AFP浓度相关性无统计学意义。外周血术前后AFP mRNA相对表达量与术后早期复发、术后无瘤生存和术后累积生存相关性有明显统计学意义。Kaplan-Meier法分析术前AFP mRNA表达低组和表达高组术后1年复发率是分别20.7%和44.7%,Log-rank法检验两组之间生存曲线总体水平有显著性差异(X2=8.868,p=0.003);术后AFP mRNA表达低组和表达高组术后1年累积复发率是分别23.4%和43.3%,总体水平有显著性差异(X~2=5.888,p=0.015)。
三、结论
1.与非解剖性肝切除相比较,解剖性肝切除可以降低术后早期复发率,提高术后早期无瘤生存率,其主要原因是:HCC的微转移灶以门静脉癌栓为主,HCC解剖性肝切除能清除更多的微转移灶。
2.与非解剖性肝切除相比较,解剖性肝切除可以减少术中出血,降低肝功能损害,减少手术并发症的发生。
3. HCC早期复发还与术中出血、微转移、术前外周血AFP mRNA和肿瘤直径密切相关。
4.实时荧光定量RT-PCR法检测HCC患者外周血AFP mRNA表达量有很高的敏感性,可以反映HCC患者血中是否存在肝癌细胞。手术可刺激HCC细胞脱落入血。监测术前外周血AFP mRNA水平对预测HCC术后早期复发转移有价值
Introduction and Objective
Currently, curative hepatectomy remains the best option for early hepatocellular carcinoma(HCC).However, there are two types hepatectomy for HCC, one is anatomical hepatectomy and the other is non-anatomical hepatectomy. The anatomical hepatectomy(A group) is the liver segments and lobes resection according to Couinaud’s views. The anatomic hepatectomy general isn`t need block the first hepatic hilum by Pringle method, and request dissect the hepatic-stem and the hepatic vein, then deligation and shearing them. While non- anatomical resection (B group) is the liver resection of a tumor without regard to segmental or lobar anatomy with resection margin at least 1.0cm. Non-anatomical resection usually need block hepatic blood flow by Pringle method, occlusion of hemihepatic blood flow or without occlusion the blood flow. Currently, there wasn`t final conclusion about the prognostic effect of anatomical versus non-anatomical resection for HCC. The standards of evidence based medicine of the published documents were B grade evidence or C grade evidence, without A grade evidence. To research this question, the best method is randomized controlled trial. So we designed this RCT and wanted to reveal which hepatectomy could decrease the recurrence rate, elevate the disease-free survival rate and the overall survival rate.
Pathologic large slice can be observed the process of tumour cell and constitution, junctional zone cell and constitution, normal tissue. It can be used to study the distribution, number, and distance of micrometastasis. The liver specimen go along the portal venous flow and the tumour max diameter location cross section were slivered, then manufacture the pathologic large slice of operation specimen. We studied the number,type and distance of micrometastasis, wanted to offer the pathologic evidence for operation type.
Hematogenous metastasis is the main metastasis mode of HCC. Currently, AFP mRNA was considered the useful marker of circulating tumor HCC cells. Real time fluorescent quantitation RT-PCR is the ideal method to detect the CTCs because of high performance, high specificity, high sensitivity. 5ml peripheral blood before and after hepatectomy for HCC were collected, then peripheral blood mononuclear cells (PBMCs, contain the CTCs) were extracted, and the AFP mRNA was detected by real-time fluorescent quantitative RT-PCR analysis. To compare the level change of AFP mRNA, we want to offer the cytological evidence for operation type.
Methods and Results
1. According to the including criteria, excluding criteria and randomization procedure, every HCC patient was done corresponding curative hepatectomy, collected the clinical, operation and pathology datas. All patients were followed with liver biochemistry, AFP serum samples and abdominal ultrasonography every 2 months and chest X-ray every 6 months. A CT scan was performed when a recurrence or metastasis was suspected.The patients were judged whether recurrence according to the recurrence criteria, recorded the death, then analysised whether the recurrence rate, death rate, and operation complication rate were different according to different operation type. Recurrence rates, disease-free survival rate and overall survival rates were evaluated using the Kaplan-Meier method and compared using the Log-rank test. Other factors were analysised about prognosis also.
As well as this survey, an analysis of patients with HCC who underwent curative hepatic resection at Institute of Hepatobiliary Surgery, Southwest Hospital between January 2006 and June 2007 was carried out. There were 133 patients were enrolled in this study. Anatomical resection was performed in 67 patients (A group) and non-anatomical resection( B group) in 66 patients. The follow-up by time was March 2008, and median follow-up period after the surgery was 19 months (range, 8–27 months).The following parameters were compared in two groups: patient age, sex, Child-Pugh classification, serum HBsAg, ICGR-15, serum AFP, hepatic function, number and size of tumors, Edmondson grade, liver cirrhosis and TNM grade, and no significant differences were found between A and B groups in terms of the clinicopathologic findings. Postoperative analysis of variables including tumor-free resection margin, operation hemorrhage, perioperative blood transfusion, post-operation liver function, operation time, length of hospital stay, number and type of complications, recurrence rate, death rate, disease-free survival rates, and overall survival rates. The operation hemorrhage of A group(744.8±539.0 ml)is less than that of B group(952.3±634.1 ml)(p=0.044), and the perioperative blood transfusion of A group is less than that of B group(p=0.035). The ALT and TBIL level of A group are lower than those of B group at the 3th-, 5th- post operation day. A case operation-related death occurred in each group. The numbers of complication and man-time complication in two group are 46 and 57 respectively. The complication rate was higher in B group(40.9%,27/66) than in A group (28.4%,19/67), but the difference was not significant(p=0.198). While the man-time complication rate was higher significant in B group(54.5%,36/66) than in A group (31.3%,21/67) (p=0.014). Altogether, 43 (32.3%,43/133) patients experienced tumor recurrence: 33(24.8%, 33/133) had an intrahepatic recurrence and 10(7.5%, 10/133) had an extrahepatic recurrence. The recurrence and metastasis rate was higher significant in B group(42.4%,28/66) than in A group (22.4%,15/67)(p=0.022). The mortality was higher in B group (22.7%,15/66) than in A group (14.9%,10/67), but the difference was not significant(p=0.353).By Kaplan-Meier survival analysis, the 1-year recurrence rates were 22.9% in A group and 41.8% in B group, respectively (p=0.018). The 1-year disease-free survival rates were 75.5% and 48.2%, respectively (p=0.003). The corresponding 1-year overall survival rates were 86.8% and 78.6% (p=0.277). According to univariate factor analysis, we performed the multivariate regression analysis with the Cox proportional hazard model, and multivariate analysis identified five factors (anatomic resection , micrometastasis, blood lost volume>600ml, AFP mRNA level before operation>150.0 and tumor diameter) as significantly influencing the recurrence rate, and three factors (anatomic resection , micrometastasis and tumor bouncary fuzziness ) as significantly influencing the disease-free survival rate. Anatomic resection was confirmed to be an independent favorable factor for disease-free survival.
2. The boundary, tumor amicula and macroscopic metastasis of the resection specimens were observed and recorded, and tumour diameter, RM, specimens length were measured. After the specimens were fixed, they were manufactured large pathologic slices. The number, type and distance of micrometastasises and Edmondson grade were observed by light microscope. The distances of micrometastasises on unfixed liver resection specimen were calculated again by the shrinkage rate of the fixed specimen from each specimen on the pathologic section. In this study, micrometastasis was identified as two types: (1) microscopic tumor thrombus and (2) tumor satellite micronodules.
In total, 133 patients were studied and their liver resection specimens were manufactured large pathologic slices. We observed 54.9% (73/133) resection specimens had micrometastases and found 136 micrometastases. There were 13.2% (18/136) tumor satellite micronodules and 86.8% (118/136) microscopic tumor thrombus. There were 61.0% (83/136) microscopic portal vein tumor thrombus, 15.4% (21/136) microscopic liver vein tumor thrombus and 10.3% (14/136) microscopic tumor thrombus difficulty identify. The distances median of micrometastasises was 3.6mm and range was (1.1mm-20.2mm).The intrahepatic micrometastases were correlated with tumour diameter, amicula integrity, pTNM stage and Edmondson grade, not correlated with tumor numbers and serum AFP. Altogether, 58.2% (39/67) A group patients had micrometastases and 78 micrometastases were found: 51 microscopic portal vein tumor thrombus, 10 tumor satellite micronodules, 9 microscopic liver vein tumor thrombus and 8 microscopic tumor thrombus difficulty identify. While 51.5% (34/66) B group patients had micrometastases and 58 micrometastases were found: 32 microscopic portal vein tumor thrombus, 8 tumor satellite micronodules, 12 microscopic liver vein tumor thrombus and 6 microscopic tumor thrombus difficulty identify. The micrometastases rate was no significant in A group (58.2%, 39/67) and in B group (51.5%, 34/66) (p=0.334). The numbers of micrometastases and microscopic portal vein tumor thrombus in A group were higher than those in B group with Mann-Whitney U test(p=0.043, p=0.000). By Kaplan-Meier survival analysis, the 1-year recurrence rates were 19.7% in no micrometastases group and 43.1% in micrometastases group, respectively (p=0.005). The 1-year disease-free survival rates were 76.0% and 49.4%, respectively (p=0.001). The corresponding 1-year overall survival rates were 88.5% and 78.3% (P = 0.032).
3. The 5ml peripheral vein blood from 133 HCC patients were collected before and after hepatectomy into heparin tubes, then the peripheral blood mononuclear cells (PBMCs, contain the CTCs) were extracted, the all RNA was extracted and the AFP mRNA was detected by real-time fluorescent quantitative RT-PCR analysis. The peripheral vein blood from 8 patients with hepatitis B and cirrhosis, 4 patients with hyperplasia, 8 patients with hepatic hemangioma, 10 healthy volunteers were collected and AFP mRNA were detected as control groups.
The sensitivity was determined theoretically at 1 AFP mRNA positive cell in approximately to 10~6-10~7 of mononuclear blood cells.The median data of AFP mRNA level of HCC was 3.97×10~(-3)(9.1×10~(-7)～6.52×10~(-1)), and higher significant than those of control groups(p=0.000). The median data of AFP mRNA level after hepatectomy was (1.673×10~(-2), range: 8.0×10~(-7)～5.170×10~(-1)), and higher significant than that of before hepatectomy (3.974×10~(-3), range: 9.0×10~(-7)～6.518×10~(-1)) (p=0.000). The level of AFP mRNA was no different between A group and B group before hepatectomy. The AFP mRNA level was higher in the B group (median, 2.24×10~(-2), range: 4.3×10~(-6)～5.10×10~(-1))than in A group (median, 1.35×10~(-2), range:1.32×10~(-6)～4.17×10~(-1)), but the difference was not significant (p=0.092). The AFP mRNA level before hepatectomy was correlated with tumour diameter, micrometastasis and pTNM stage, and not correlated with tumor numbers, serum AFP, amicula integrity, and Edmondson grade. The AFP mRNA level before and after hepatectomy were correlated with recurrence, disease-free survival and overall survival. By Kaplan-Meier survival analysis, the 1-year recurrence rates were 20.7% in the low AFP mRNA level before hepatectomy group and 44.7% in the high AFP mRNA level before hepatectomy group, respectively (p=0.003). By Kaplan-Meier survival analysis, the 1-year recurrence rates were 23.4% in the low AFP mRNA level after hepatectomy group and 43.3% in the high AFP mRNA level after hepatectomy group, respectively (p=0.015).
Conclusions
1. Compare to non-anatomical hepatectomy, anatomical hepatectomy can degrade the early recurrence rate and elevate the early disease-free survival rates. The main reason is that the micrometastasis of HCC are mostly microscopic portal vein tumor thrombus and anatomical hepatectomy can clear more micrometastasis.
2. Compare to non-anatomical hepatectomy, anatomical hepatectomy can decrease operation hemorrhage, depress the liver function lesion, decrease complication.
3. The other early recurrence factors of HCC are operation hemorrhage, micrometastasis, AFP mRNA level before hepatectomy and tumor diameter.
4. Analysis of AFP mRNA by real-time fluorescent quantitative RT-PCR is a very sensitive method for detecting circulating HCC cells,and can indicate the presence of hematogenous metastasis in patients with HCC. HCC cells can be released into the blood circulation because of hepatectomy. Monitoring AFP mRNA in peripheral vein blood may predict recurrence and prognosis for HCC.
对于早期HCC的治疗,目前学术界公认根治性切除是其最佳选择,而根治性切除术的术式有两种:解剖性肝切除术和非解剖性肝切除术。解剖性肝切除术是指:按照肝脏Couinaud分段进行肝切除术,包括单肝段切除及多肝段切除;解剖性肝切除术一般不需要Pringle法阻断第一肝门,关键是解剖出进入肝段的肝蒂和出肝静脉,分别予以结扎然后切除肝段。而非解剖性肝切除术定义为:完整切除肿瘤不考虑肝内解剖,一般要求切缘(RM)至少1.0cm。非解剖性肝切除术一般需要Pringle法阻断第一肝门或者半肝阻断,也可以不阻断第一肝门。目前国内外关于HCC手术方式对预后影响仍无定论。从循证医学的标准界定已经发表的国内外文献临床证据级别是B级或C级,未发现A级的临床证据。为了研究术式对HCC预后的影响,最佳的方法是应用临床随机对照研究(RCT),比较解剖性肝切除与非解剖性肝切除哪种术式更能减少术后复发,提高HCC术后无瘤生存率和累积生存率,从而为HCC根治性切除术的术式选择提供A级的证据。
大病理切片可以清楚的显示瘤体结构、交界区结构和“正常组织”区的连续过程。用于研究微转移的分布、数目、距离瘤体的距离等,较普通的病理切片有明显的优点。本研究沿在肝内门静脉血流方向的瘤体最大直径所在切面切开标本,行大病理切片检查,研究HCC微转移灶的数目、类型和转移距离及癌细胞Edmondson分级,为术式的选择提供病理学的证据。
血源性转移是HCC转移复发的主要方式。目前AFP mRNA被认为是比较有价值的循环HCC细胞标志物。实时荧光定量RT-PCR技术以其高效性、高特异性、高敏感性及计量准确等优点,成为目前检测CTCs的理想工具。手术可以刺激HCC细胞入外周血循环,因此收集HCC患者手术前后外周静脉血,提取外周血单核细胞(PBMCs,包含CTCs),采用实时荧光定量RT-PCR技术,检测外周血AFP mRNA手术前后的变化,估计两种术式外周血中CTCs数量变化是否有差异,为术式的选择提供细胞学的证据。
二、方法与结果
1.根据术前制定的患者纳入和排除标准,按照随机化的要求,每一个入组的HCC患者行相应的肝脏根治性切除术,收集临床、手术、病理资料,每2月随访1次,测定肝功能、血AFP和肝脏超声检查,每6个月检查胸片1次,怀疑复发时行肝脏或肺部CT检查。根据制定的判断复发标准界定有无复发,记录是否生存。结合随访信息,分析术式不同,术后复发率、术后死亡率、手术并发症的发生率是否不同;并采用Kaplan-Meier法生存分析,Log-rank法检验两组之间的术后早期复发率、术后早期无瘤生存率、术后早期累积生存率的生存曲线总体水平有无差异。本研究还分析了与预后有关的其他因素。
本研究自2006年1月1日起到2007年6月30日止,共纳入就诊于重庆西南医院肝胆外科研究所符合要求病例133例,其中解剖性肝切除67例,非解剖性肝切除66例。随访截至到2008年3月31日,中位随访时间是19个月(8～27个月),其中失访3例。两组的性别、年龄、HBV感染、Child-Pugh分级、ICGR-15、血AFP、术前肝功能、肿瘤直径、肿瘤包膜、肿瘤数目、HCC分级、肝硬化、TNM分级等一般情况和病理检查结果无统计学差异,说明两组具有可比性。术后分析的有关变量包括:两组手术切缘、手术出血量、围手术期输血量、术后肝功能、手术时间、住院时间、手术并发症、复发率、死亡率、无瘤生存和累积生存。解剖组术中出血量明显低于非解剖组,分别是(744.8±539.0)ml和(952.3±634.1)ml(p=0.044);两组围手术期输血量的中位数分别是0(0-5100)ml和600(0-4660)ml,解剖组明显低于非解剖组(p=0.035)。术后1天和5天的血ALT和TBIL值,解剖组也明显低于非解剖组。每组各有1例患者死于手术并发症。两组术后共46(34.6%, 46/133)人发生手术并发症,共发生57人次,其中解剖组19(28.4%, 19/67)人共21人次;非解剖组27(40.9%, 27/66)人共36人次。发生人数比例经过X2检验,两组无统计学差异(X~2=1.658, p=0.198);但发生人次比例经过X2检验,两组有明显统计学差异(X~2=6.045, p=0.014),说明解剖性肝切除术更能减少手术并发症的发生。两组共有43例发生复发或转移,占32.3%(43/133),其中肝内复发33例,占24.8%(33/133);肺部、椎骨或后腹膜等肝外转移10例占7.5%(10/133)。解剖组复发转移15例,占本组的22.4%(15/67);而非解剖组复发转移28例,占本组的42.4%(28/66),经X2检验,有明显统计学差异(X2=5.219,p=0.022)。共死亡25人,占18.8%(25/133),包括解剖组1例围手术期死于肝功能衰竭,非解剖组1例围手术期死于上消化道大出血。解剖组死亡10例,占本组的14.9%(10/67);而非解剖组死亡15例,占本组的22.7%(15/66),经X~2检验,无统计学差异(X2=0.864, p=0.353)。Kaplan-Meier法分析解剖组和非解剖组术后1年累积复发率是分别22.9%和41.8%,Log-rank法检验两组之间生存曲线总体水平有显著性差异(X2=5.614, p=0.018);解剖组和非解剖组术后1年无瘤生存率分别是75.5%和48.2%,总体水平有显著性差异(X2=8.601, p=0.003);解剖组和非解剖组术后1年累积生存率分别是86.8%和78.6%,总体水平无显著性差异(X~2=1.184, p=0.277)。结合单因素分析结果,COX回归模型多因素分析表明:HCC术后复发与手术方式、微转移、失血量、术前外周血AFP mRNA和肿瘤直径统计学明显相关。结合单因素分析结果,COX回归模型多因素分析表明:HCC术后早期无瘤生存率与手术方式、微转移和肿瘤边界是否清楚等3因素统计学明显相关。
2.观察并记录HCC切除标本肿瘤边界是否清楚、有无肿瘤包膜、有无肉眼转移灶,测量肿瘤直径、切缘距离、标本长度,标本固定后做成大病理切片,光学显微镜观察微转移数目、类型、测定微转移的距离及肿瘤细胞分级。运用组织等比回缩规律,换算出新鲜活体标本的微转移距离。本研究微转移分为两种:微癌栓和微卫星灶。本研究133例患者都进行了大病理切片检查。54.9% (73/133)患者的标本中发现微转移灶。在73例大标本肿瘤外肝组织内共检出了136个微转移:其中13.2%(18/136)为微卫星灶,86.8%(118/136)为微癌栓。在这136个微转移中,61.0%(83/136)为门静脉癌栓,15.4%(21/136)为肝静脉癌栓,还有10.3%(14/136)的癌栓难以分辨是门静脉还是肝静脉。肿瘤扩散距离的中位数是3.6mm,范围是1.1mm～20.2mm。肝内有无微转移与肿瘤大小、包膜完整性、TNM分期、癌细胞分化程度的相关性有统计学意义;与血清AFP浓度、肿瘤数目的相关性无统计学意义。解剖组共有39例(58.2%)患者发现微转移,共发现微转移灶78个,其中门静脉癌栓51个,肝静脉癌栓9个,其他癌栓8个,卫星灶10个。非解剖组共有34(51.5%)例患者发现微转移,共发现微转移灶58个,其中门静脉癌栓32个,肝静脉癌栓12个,其他癌栓6个,卫星灶8个。两组发现微转移病例数经X2检验无统计学差异(X~2=0.935,p=0.334)。两组微转移总数和门静脉癌栓数经过Mann-Whitney U检验有统计学差异(p=0.043和p=0.000)。Kaplan-Meier法分析无微转移组和有微转移组术后1年复发率是分别19.7%和43.1%,Log-rank法检验两组之间生存曲线总体水平有显著性差异(X~2=8.037, p=0.005);无微转移组和有微转移组术后1年无瘤生存率分别是76.0%和49.4%,总体水平有显著性差异(X~2=10.996,p=0.001);无微转移组和有微转移组术后1年累积生存率分别是88.5%和78.3%,总体水平有显著性差异(X~2=4.579, p=0.032)。
3.分别在术前和术后抽取133患者的5ml外周静脉血,肝素抗凝,收集PBMCs(包含CTCs),提取PBMCc的总RNA,利用实时荧光定量RT-PCR技术,检测外周血AFP mRNA在手术前后的变化。我们还检测了8例肝硬化、4例肝增生、8例肝血管瘤和10例健康志愿者外周血AFP mRNA的含量作为对照。研究表明实时荧光定量RT-PCR检测外周血微转移癌细胞的敏感性可以达1/10~6-10~7。HCC组的外周血AFP mRNA相对表达量中位数是3.97×10~(-3)(9.1×10~(-7)～6.52×10~(-1)),明显高于肝硬化组、肝血管瘤组、肝脏增生组和健康对照组,差异有统计学意义(p=0.000)。HCC患者术后外周血AFP mRNA相对表达量的中位数是:1.673×10~(-2)(范围8.0×10~(-7)～5.170×10~(-1)),明显高于术前3.974×10~(-3)(范围9.0×10~(-7)～6.518×10~(-1))的水平(p=0.000)。经过统计学分析,两组手术前外周血AFP mRNA水平无统计学差异。非解剖组术后外周血AFP mRNA水平的中位数是2.24×10~(-2) (范围4.3×10~(-7)～5.10×10~(-1)),而解剖组是1.35×10~(-2) (范围1.32×10~(-6)～4.17×10~(-1)),非解剖组高于解剖组,但是无统计学差异(p=0.092)。HCC组术前AFP mRNA水平相对表达量与TNM分期、微转移、肿瘤大小有明显统计学意义(p=0.003, p=0.002和p=0.000),与肿瘤数目、包膜完整性均、癌细胞分化程度与血清AFP浓度相关性无统计学意义。外周血术前后AFP mRNA相对表达量与术后早期复发、术后无瘤生存和术后累积生存相关性有明显统计学意义。Kaplan-Meier法分析术前AFP mRNA表达低组和表达高组术后1年复发率是分别20.7%和44.7%,Log-rank法检验两组之间生存曲线总体水平有显著性差异(X2=8.868,p=0.003);术后AFP mRNA表达低组和表达高组术后1年累积复发率是分别23.4%和43.3%,总体水平有显著性差异(X~2=5.888,p=0.015)。
三、结论
1.与非解剖性肝切除相比较,解剖性肝切除可以降低术后早期复发率,提高术后早期无瘤生存率,其主要原因是:HCC的微转移灶以门静脉癌栓为主,HCC解剖性肝切除能清除更多的微转移灶。
2.与非解剖性肝切除相比较,解剖性肝切除可以减少术中出血,降低肝功能损害,减少手术并发症的发生。
3. HCC早期复发还与术中出血、微转移、术前外周血AFP mRNA和肿瘤直径密切相关。
4.实时荧光定量RT-PCR法检测HCC患者外周血AFP mRNA表达量有很高的敏感性,可以反映HCC患者血中是否存在肝癌细胞。手术可刺激HCC细胞脱落入血。监测术前外周血AFP mRNA水平对预测HCC术后早期复发转移有价值
Introduction and Objective
Currently, curative hepatectomy remains the best option for early hepatocellular carcinoma(HCC).However, there are two types hepatectomy for HCC, one is anatomical hepatectomy and the other is non-anatomical hepatectomy. The anatomical hepatectomy(A group) is the liver segments and lobes resection according to Couinaud’s views. The anatomic hepatectomy general isn`t need block the first hepatic hilum by Pringle method, and request dissect the hepatic-stem and the hepatic vein, then deligation and shearing them. While non- anatomical resection (B group) is the liver resection of a tumor without regard to segmental or lobar anatomy with resection margin at least 1.0cm. Non-anatomical resection usually need block hepatic blood flow by Pringle method, occlusion of hemihepatic blood flow or without occlusion the blood flow. Currently, there wasn`t final conclusion about the prognostic effect of anatomical versus non-anatomical resection for HCC. The standards of evidence based medicine of the published documents were B grade evidence or C grade evidence, without A grade evidence. To research this question, the best method is randomized controlled trial. So we designed this RCT and wanted to reveal which hepatectomy could decrease the recurrence rate, elevate the disease-free survival rate and the overall survival rate.
Pathologic large slice can be observed the process of tumour cell and constitution, junctional zone cell and constitution, normal tissue. It can be used to study the distribution, number, and distance of micrometastasis. The liver specimen go along the portal venous flow and the tumour max diameter location cross section were slivered, then manufacture the pathologic large slice of operation specimen. We studied the number,type and distance of micrometastasis, wanted to offer the pathologic evidence for operation type.
Hematogenous metastasis is the main metastasis mode of HCC. Currently, AFP mRNA was considered the useful marker of circulating tumor HCC cells. Real time fluorescent quantitation RT-PCR is the ideal method to detect the CTCs because of high performance, high specificity, high sensitivity. 5ml peripheral blood before and after hepatectomy for HCC were collected, then peripheral blood mononuclear cells (PBMCs, contain the CTCs) were extracted, and the AFP mRNA was detected by real-time fluorescent quantitative RT-PCR analysis. To compare the level change of AFP mRNA, we want to offer the cytological evidence for operation type.
Methods and Results
1. According to the including criteria, excluding criteria and randomization procedure, every HCC patient was done corresponding curative hepatectomy, collected the clinical, operation and pathology datas. All patients were followed with liver biochemistry, AFP serum samples and abdominal ultrasonography every 2 months and chest X-ray every 6 months. A CT scan was performed when a recurrence or metastasis was suspected.The patients were judged whether recurrence according to the recurrence criteria, recorded the death, then analysised whether the recurrence rate, death rate, and operation complication rate were different according to different operation type. Recurrence rates, disease-free survival rate and overall survival rates were evaluated using the Kaplan-Meier method and compared using the Log-rank test. Other factors were analysised about prognosis also.
As well as this survey, an analysis of patients with HCC who underwent curative hepatic resection at Institute of Hepatobiliary Surgery, Southwest Hospital between January 2006 and June 2007 was carried out. There were 133 patients were enrolled in this study. Anatomical resection was performed in 67 patients (A group) and non-anatomical resection( B group) in 66 patients. The follow-up by time was March 2008, and median follow-up period after the surgery was 19 months (range, 8–27 months).The following parameters were compared in two groups: patient age, sex, Child-Pugh classification, serum HBsAg, ICGR-15, serum AFP, hepatic function, number and size of tumors, Edmondson grade, liver cirrhosis and TNM grade, and no significant differences were found between A and B groups in terms of the clinicopathologic findings. Postoperative analysis of variables including tumor-free resection margin, operation hemorrhage, perioperative blood transfusion, post-operation liver function, operation time, length of hospital stay, number and type of complications, recurrence rate, death rate, disease-free survival rates, and overall survival rates. The operation hemorrhage of A group(744.8±539.0 ml)is less than that of B group(952.3±634.1 ml)(p=0.044), and the perioperative blood transfusion of A group is less than that of B group(p=0.035). The ALT and TBIL level of A group are lower than those of B group at the 3th-, 5th- post operation day. A case operation-related death occurred in each group. The numbers of complication and man-time complication in two group are 46 and 57 respectively. The complication rate was higher in B group(40.9%,27/66) than in A group (28.4%,19/67), but the difference was not significant(p=0.198). While the man-time complication rate was higher significant in B group(54.5%,36/66) than in A group (31.3%,21/67) (p=0.014). Altogether, 43 (32.3%,43/133) patients experienced tumor recurrence: 33(24.8%, 33/133) had an intrahepatic recurrence and 10(7.5%, 10/133) had an extrahepatic recurrence. The recurrence and metastasis rate was higher significant in B group(42.4%,28/66) than in A group (22.4%,15/67)(p=0.022). The mortality was higher in B group (22.7%,15/66) than in A group (14.9%,10/67), but the difference was not significant(p=0.353).By Kaplan-Meier survival analysis, the 1-year recurrence rates were 22.9% in A group and 41.8% in B group, respectively (p=0.018). The 1-year disease-free survival rates were 75.5% and 48.2%, respectively (p=0.003). The corresponding 1-year overall survival rates were 86.8% and 78.6% (p=0.277). According to univariate factor analysis, we performed the multivariate regression analysis with the Cox proportional hazard model, and multivariate analysis identified five factors (anatomic resection , micrometastasis, blood lost volume>600ml, AFP mRNA level before operation>150.0 and tumor diameter) as significantly influencing the recurrence rate, and three factors (anatomic resection , micrometastasis and tumor bouncary fuzziness ) as significantly influencing the disease-free survival rate. Anatomic resection was confirmed to be an independent favorable factor for disease-free survival.
2. The boundary, tumor amicula and macroscopic metastasis of the resection specimens were observed and recorded, and tumour diameter, RM, specimens length were measured. After the specimens were fixed, they were manufactured large pathologic slices. The number, type and distance of micrometastasises and Edmondson grade were observed by light microscope. The distances of micrometastasises on unfixed liver resection specimen were calculated again by the shrinkage rate of the fixed specimen from each specimen on the pathologic section. In this study, micrometastasis was identified as two types: (1) microscopic tumor thrombus and (2) tumor satellite micronodules.
In total, 133 patients were studied and their liver resection specimens were manufactured large pathologic slices. We observed 54.9% (73/133) resection specimens had micrometastases and found 136 micrometastases. There were 13.2% (18/136) tumor satellite micronodules and 86.8% (118/136) microscopic tumor thrombus. There were 61.0% (83/136) microscopic portal vein tumor thrombus, 15.4% (21/136) microscopic liver vein tumor thrombus and 10.3% (14/136) microscopic tumor thrombus difficulty identify. The distances median of micrometastasises was 3.6mm and range was (1.1mm-20.2mm).The intrahepatic micrometastases were correlated with tumour diameter, amicula integrity, pTNM stage and Edmondson grade, not correlated with tumor numbers and serum AFP. Altogether, 58.2% (39/67) A group patients had micrometastases and 78 micrometastases were found: 51 microscopic portal vein tumor thrombus, 10 tumor satellite micronodules, 9 microscopic liver vein tumor thrombus and 8 microscopic tumor thrombus difficulty identify. While 51.5% (34/66) B group patients had micrometastases and 58 micrometastases were found: 32 microscopic portal vein tumor thrombus, 8 tumor satellite micronodules, 12 microscopic liver vein tumor thrombus and 6 microscopic tumor thrombus difficulty identify. The micrometastases rate was no significant in A group (58.2%, 39/67) and in B group (51.5%, 34/66) (p=0.334). The numbers of micrometastases and microscopic portal vein tumor thrombus in A group were higher than those in B group with Mann-Whitney U test(p=0.043, p=0.000). By Kaplan-Meier survival analysis, the 1-year recurrence rates were 19.7% in no micrometastases group and 43.1% in micrometastases group, respectively (p=0.005). The 1-year disease-free survival rates were 76.0% and 49.4%, respectively (p=0.001). The corresponding 1-year overall survival rates were 88.5% and 78.3% (P = 0.032).
3. The 5ml peripheral vein blood from 133 HCC patients were collected before and after hepatectomy into heparin tubes, then the peripheral blood mononuclear cells (PBMCs, contain the CTCs) were extracted, the all RNA was extracted and the AFP mRNA was detected by real-time fluorescent quantitative RT-PCR analysis. The peripheral vein blood from 8 patients with hepatitis B and cirrhosis, 4 patients with hyperplasia, 8 patients with hepatic hemangioma, 10 healthy volunteers were collected and AFP mRNA were detected as control groups.
The sensitivity was determined theoretically at 1 AFP mRNA positive cell in approximately to 10~6-10~7 of mononuclear blood cells.The median data of AFP mRNA level of HCC was 3.97×10~(-3)(9.1×10~(-7)～6.52×10~(-1)), and higher significant than those of control groups(p=0.000). The median data of AFP mRNA level after hepatectomy was (1.673×10~(-2), range: 8.0×10~(-7)～5.170×10~(-1)), and higher significant than that of before hepatectomy (3.974×10~(-3), range: 9.0×10~(-7)～6.518×10~(-1)) (p=0.000). The level of AFP mRNA was no different between A group and B group before hepatectomy. The AFP mRNA level was higher in the B group (median, 2.24×10~(-2), range: 4.3×10~(-6)～5.10×10~(-1))than in A group (median, 1.35×10~(-2), range:1.32×10~(-6)～4.17×10~(-1)), but the difference was not significant (p=0.092). The AFP mRNA level before hepatectomy was correlated with tumour diameter, micrometastasis and pTNM stage, and not correlated with tumor numbers, serum AFP, amicula integrity, and Edmondson grade. The AFP mRNA level before and after hepatectomy were correlated with recurrence, disease-free survival and overall survival. By Kaplan-Meier survival analysis, the 1-year recurrence rates were 20.7% in the low AFP mRNA level before hepatectomy group and 44.7% in the high AFP mRNA level before hepatectomy group, respectively (p=0.003). By Kaplan-Meier survival analysis, the 1-year recurrence rates were 23.4% in the low AFP mRNA level after hepatectomy group and 43.3% in the high AFP mRNA level after hepatectomy group, respectively (p=0.015).
Conclusions
1. Compare to non-anatomical hepatectomy, anatomical hepatectomy can degrade the early recurrence rate and elevate the early disease-free survival rates. The main reason is that the micrometastasis of HCC are mostly microscopic portal vein tumor thrombus and anatomical hepatectomy can clear more micrometastasis.
2. Compare to non-anatomical hepatectomy, anatomical hepatectomy can decrease operation hemorrhage, depress the liver function lesion, decrease complication.
3. The other early recurrence factors of HCC are operation hemorrhage, micrometastasis, AFP mRNA level before hepatectomy and tumor diameter.
4. Analysis of AFP mRNA by real-time fluorescent quantitative RT-PCR is a very sensitive method for detecting circulating HCC cells,and can indicate the presence of hematogenous metastasis in patients with HCC. HCC cells can be released into the blood circulation because of hepatectomy. Monitoring AFP mRNA in peripheral vein blood may predict recurrence and prognosis for HCC.
引文
1 Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends[J]. Gastroenterology, 2004,127(5 Suppl 1):S5-S16.
2陈建国,宋新明.中国肝癌发病水平的估算及分析[J].中国肿瘤, 2005,14(1): 28-31.
3张思维,李连弟,鲁凤珠,等.中国1990～1992年原发性肝癌死亡调查分析[J].中华肿瘤杂志, 1999,21(4): 245-249.
4丛文铭,吴孟超,王一,等.肝脏肿瘤3160例临床病理研究[J].中华病理学杂志, 1997,26(2): 70-73.
5 Healey JE Jr, Schroy PC. Anatomy of the biliary ducts within the human liver: analysis of the prevailing pattern of branchings and the major variations of the biliary ducts[J]. Arch Surg, 1953,66:599-616.
6 Healey JE. Clinical anatomic aspects of radical hepatic surgery[J]. J Int Coll Surg, 1954,22:542-550.
7 Couinaud C,Le Foie. Etudes Anatomiques et Chirurgicales[A]. Paris:Masson&Cie, 1957, 284-289.
8 Couinaud C. Surgical anatomy of the liver revisited ch 4. anatomy of the dorsal sector of the liver. New considerations on liver anatomy[A]. Paris: Pers Ed, 1989. 26-39.
9 Cahill BA, Braccia D. Current treatment for hepatocellular carcinoma[J]. Clin J Oncol Nurs, 2004,8(4):393-9.
10 Yanaga K. Current status of hepatic resection for hepatocellular carcinoma[J]. J Gastroenterol, 2004,39(10):919-926.
11 Poon RT, Fan ST, Ng IO, et al. Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal[J]. Ann Surg, 2000,231(4):544-551.
12吴孟超.原发性肝癌外科综合治疗的现状和展望[J].中华外科杂志, 2004,42(1): 13-15.
13 Hasegawa K, Kokudo N, Imamura H, et al. Prognostic impact of anatomic resection for hepatocellular carcinoma[J]. Ann Surg, 2005,242(2):252-259.
14 Suh KS. Systematic hepatectomy for small hepatocellular carcinoma in Korea[J]. J Hepatobiliary Pancreat Surg, 2005,12(5):365-370.
15 Capussotti L, Muratore A, Amisano M, et al. Liver resection for hepatocellularcarcinoma on cirrhosis: analysis of mortality, morbidity and survival--a European single center experience[J]. Eur J Surg Oncol, 2005,31(9):986-993.
16 Shi M, Zhang CQ, Zhang YQ, et al. Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin[J]. World J Surg, 2004,28(4):376-381.
17 Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey[J]. Cancer, 2004,101(4):796-802.
18 Poon RT, Fan ST, Ng IO, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma[J]. Cancer, 2000,89(3):500-507.
19 Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy[J]. J Hepatol, 2003,38(2):200-207.
20 Kamiyama T, Takahashi M, Nakagawa T, et al. AFP mRNA detected in bone marrow by real-time quantitative RT-PCR analysis predicts survival and recurrence after curative hepatectomy for hepatocellular carcinoma[J]. Ann Surg, 2006,244(3): 451-463.
21 Wong IH, Yeo W, Leung T, et al. Circulating tumor cell mRNAs in peripheral blood from hepatocellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: a quantitative evaluation[J]. Caner Lett, 2001,167(2):183-191.
22 Wang YL, Li G, Wu D, et al. Analysis of alpha-fetoprotein mRNA level on the tumor cell hematogenous spread of patients with hepatocellular carcinoma undergoing orthotopic liver transplantation[J]. Transplant Proc, 2007,39(1):166-168.
23蒋知俭.医学统计学[M].第1版.北京:人民卫生出版社,1997. 572.
24 Liau KH, Blumgart LH, DeMatteo RP. Segment-oriented approach to liver resection[J]. Surg Clin North Am, 2004,84(2):543-561.
25 Billingsley KG, Jarnagin WR, Fong Y, et al. Segment-oriented hepatic resection in the management of malignant neoplasms of the liver[J]. J Am Coll Surg, 1998, 187(5):471-481.
26 Sobin LH, Wittekind C, eds, ed. International Union Against Cancer (IUAC).TNM classification of malignant tumors.6th ed[M]. New York:Wiley-Liss,2002. 81-83.
27彭淑牖,冯雪冬,刘颖斌,等.肝尾状叶原发性肝细胞肝癌的外科治疗[J].中华外科杂志, 2005,43(1): 49-52.
28黄志强,周宁新,黄晓强,等.尾状叶外科———肝外科的最后领域[J].消化外科, 2004,3(1): 1-17.
29 Imamura H, Sano K, Sugawara Y, et al. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test[J]. J Hepatobiliary Pancreat Surg, 2005,12(1):16-22.
30 Fan ST. Methods and related drawbacks in the estimation of surgical risks in cirrhotic patients undergoing hepatectomy[J]. Hepatogastroenterology, 2002,49(43):17-20.
31 Van Thiel DH, Wright HI, Fagiuoli S, et al. Preoperative evaluation of a patient for hepatic surgery[J]. J Surg Oncol Suppl, 1993,3:49-51.
32 Lam CM, Fan ST, Lo CM, et al. Major hepatectomy for hepatocellular carcinoma in patients with an unsatisfactory indocyanine green clearance test[J]. Br J Surg, 1999,86(8):1012-1017.
33 Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg, 1973,60(8):646-649.
34戴朝六.肝脏储备功能的评估[J].中国实用外科杂志, 2005,25(12): 708-710.
35 Hanazaki K, Matsushita A, Nakagawa K, et al. Risk factors of long-term survival and recurrence after curative resection of hepatocellular carcinoma[J]. Hepatogastroenterology, 2005,52(62):552-557.
36 Hanazaki K, Kajikawa S, Shimozawa N, et al. Perioperative blood transfusion and survival following curative hepatic resection for hepatocellular carcinoma[J]. Hepatogastroenterology, 2005,52(62):524-529.
37袁爱军黄兴耀.肝癌切除术中的外科切缘(附544例分析)[J].中国实用外科杂志, 2001,21(4): 220-221.
38吴福生,赵文和,梁廷波,等.影响3cm以下小肝癌患者术后生存因素的观察[J].中华外科杂志, 2005,43(9): 579-583.
39周学平,杨广顺,丛文铭,等.原发性肝癌瘤周肝组织内微转移的回顾性与前瞻性研究[J].中华肝胆外科杂志, 2005,11(8): 510-514.
40徐立,石明,张亚奇,等.肝细胞癌手术切缘对患者术后复发与生存的影响[J].中华肿瘤杂志, 2006,28(1): 47-49.
41李升平,张昌卿,冯凯涛,等.肝癌亚临床转移灶及临床病理学意义的研究[J].中国肿瘤临床, 2002,29(2): 77-81.
42 Kosuge T, Makuuchi M, Takayama T, et al. Long-term results after resection of hepatocellular carcinoma: experience of 480 cases[J]. Hepatogastroenterology, 1993,40(4):328-332.
43 Wu CC, Hwang CJ, Yang MD, et al. Preliminary results of hepatic resection for centrally located large hepatocellular carcinoma[J]. Aust N Z J Surg, 1993,63(7):525-529.
44 Ochiai T, Takayama T, Inoue K, et al. Hepatic resection with and without surgical margins for hepatocellular carcinoma in patients with impaired liver function[J]. Hepatogastroenterology, 1999,46(27):1885-1889.
45 Shimada M, Gion T, Hamatsu T, et al. Evaluation of major hepatic resection for small hepatocellular carcinoma[J]. Hepatogastroenterology, 1999,46(25):401-406.
46 Cho YB, Lee KU, Lee HW, et al. Anatomic versus non-anatomic resection for small single hepatocellular carcinomas[J]. Hepatogastroenterology, 2007,54(78):1766-1769.
47 Ochiai T, Sonoyama T, Kikuchi S, et al. Anatomic wide hepatectomy for treatment of hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2007,133(8):563-569.
48 Yamashita Y, Taketomi A, Itoh S, et al. Longterm favorable results of limited hepatic resections for patients with hepatocellular carcinoma: 20 years of experience[J]. J Am Coll Surg, 2007,205(1):19-26.
49林贵.肝肿瘤微血管结构和血供[J].中华放射学杂志, 1985,19: 257-260.
50 Ishida H, Iwama T, Yoshinaga K, et al. Bromodeoxyuridine uptake by early liver metastases in rats: a comparison of the hepatic artery and portal vein infusion routes[J]. Surg Today, 1998,28(8):822-829.
51 Taniguchi H, Daidoh T, Shioaki Y, et al. Blood supply and drug delivery to primary and secondary human liver cancers studied with in vivo bromodeoxyuridine labeling[J]. Cancer, 1993,71(1):50-55.
52 Toyosaka A, Okamoto E, Mitsunobu M, et al. Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as an efferent vessel[J]. Am J Gastroenterol, 1996,91(8):1610-1615.
53 Toyosaka A, Okamoto E, Mitsunobu M, et al. Pathologic and radiographic studies ofintrahepatic metastasis in hepatocellular carcinoma; the role of efferent vessels[J]. HPB Surg, 1996,10(2):97-103; discussion 103-104.
54 Takizawa D, Kakizaki S, Sohara N, et al. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis[J]. Dig Dis Sci, 2007,52(11):3290-3295.
55 Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials[J]. Hepatology, 1999,29(1):62-67.
56 Sumie S, Kuromatsu R, Okuda K, et al. Microvascular Invasion in Patients with Hepatocellular Carcinoma and Its Predictable Clinicopathological Factors[J]. Ann Surg Oncol, 2008.
57吴孟超,陈汉,沈锋.原发性肝癌的外科治疗--附5524例报告[J].中华外科杂志, 2001,39(1): 25-28.
58 Lee HH, Joh JW, Park JH, et al. Microvascular tumor embolism: independent prognostic factor after liver transplantation in hepatocellular carcinoma[J]. Transplant Proc, 2005,37(2):1251-1253.
59 Chau GY, Lui WY, Wu CW. Spectrum and significance of microscopic vascular invasion in hepatocellular carcinoma[J]. Surg Oncol Clin N Am, 2003,12(1):25-34.
60樊嘉,汤钊猷,吴志全,等.门静脉微癌栓和肉眼癌栓对肝癌患者术后生存的影响[J].中华外科杂志, 2005,43(7): 433-435.
61刘允怡,余俊豪.肝段为本的肝切除手术[J].中华普通外科杂志, 2003,18(2): 123-125.
62 Wong IH, Yeo W, Leung T,et al. Circulating tumor cell mRNAs in peripheral blood from hepatocellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: a quantitative evaluation[J]. Cancer Lett, 2001,167(2):183-191.
63 Farges O, Regimbeau JM, Belghiti J. Aggressive management of recurrence following surgical resection of hepatocellular carcinoma[J]. Hepatogastroenterology, 1998,45 Suppl 3:1275-1280.
64黎乐群,彭涛,林进令,等.复发性肝细胞癌的细胞克隆来源及其与复发时间的关系[J].中华肝胆外科杂志, 1999,5(1): 11-13.
65 Sirivatanauksorn Y, Sirivatanauksorn V, Bhattacharya S, et al. Genomic heterogeneityin synchronous hepatocellular carcinomas[J]. Gut, 1999,45(5):761-765.
66 Hanazaki K, Kajikawa S, Koide N, et al. Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis[J]. Am J Gastroenterol, 2001,96(4):1243-1250.
67吴育连,苏昆仑,董鑫,等.肝癌切除术后早/晚期复发的危险因素与治疗[J].中华肝胆外科杂志, 2006,12(6): 370-373.
68 Grazi GL, Cescon M, Ravaioli M, et al. Liver resection for hepatocellular carcinoma in cirrhotics and noncirrhotics. Evaluation of clinicopathologic features and comparison of risk factors for long-term survival and tumour recurrence in a single centre[J]. Aliment Pharmacol Ther, 2003,17 Suppl 2:119-129.
69周信达,汤钊猷,杨秉辉,等. 1000例小肝癌手术切除经验[J].中国实用外科杂志, 2001,21(1): 41-44.
70 Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma[J]. Liver Transpl, 2005,11(9):1086-1092.
71 Hu RH, Lee PH, Chang YC, et al. Prognostic factors for hepatocellular carcinoma < or = 3 cm in diameter[J]. Hepatogastroenterology, 2003,50(54):2043-2048.
72 Nakashima Y, Nakashima O, Tanaka M, et al. Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type[J]. Hepatol Res, 2003,26(2):142-147.
73吴福生,赵文和,梁廷波,等.影响3 cm以下小肝癌患者术后生存因素的观察[J].中华外科杂志, 2005,43(9): 579-583.
74 Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years[J]. Ann Surg, 2001,234(1):63-70.
75 Zhou XD. Recurrence and metastasis of hepatocellular carcinoma: progress and prospects[J]. Hepatobiliary Pancreat Dis Int, 2002,1(1):35-41.
76 Yeh CN, Lee WC, Jeng LB, et al. Hepatic resection for hepatocellular carcinoma in Taiwan[J]. Eur J Surg Oncol, 2002,28(6):652-656.
77 Makino Y, Yamanoi A, Kimoto T, et al. The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellularcarcinoma[J]. Am J Gastroenterol, 2000,95(5):1294-1300.
78 Kwon AH, Matsui Y, Kamiyama Y. Perioperative blood transfusion in hepatocellular carcinomas: influence of immunologic profile and recurrence free survival[J]. Cancer, 2001,91(4):771-778.
79 Sabalic S, Kovacevic D, Glavic Z, et al. The immunomodulation effect of allogenic blood transfusion in colorectal cancer--a new approach[J]. Coll Antropol, 2006,30(4):885-893.
80 Uchida H, Tanaka H, Kitoh Y, et al. Mechanisms of immunomodulation induced by blood transfusion: identification of humoral factors[J]. Transplant Proc, 2000,32(2):255-256.
81苏永杰,董家鸿,李海林,等. TissueLink与钳夹法在肝癌切除术中的应用比较[J].中国现代普通外科进展, 2008,11(1): 7-9.
82 Sakamoto Y, Yamamoto J, Kokudo N, et al. Bloodless liver resection using the monopolar floating ball plus ligasure diathermy: preliminary results of 16 liver resections[J]. World J Surg, 2004,28(2):166-172.
83 Hermanek P,Henson D,Hutter R,SobinL,editors. International Union Against Cancer.TNM Supplement 1993. A commentary on uniform use[M]. Berlin: Springer, 1993.
84 Page DL, Anderson TJ, Carter BA. Minimal solid tumor involvement of regional and distant sites: when is a metastasis not a metastasis?[J]. Cancer, 1999,86(12):2589-2592.
85 Lindsay CK, Sinha CC, Thorgeirsson UP. Morphological study of vascular dissemination in a metastatic hepatocellular carcinoma model in the monkey[J]. Hepatology, 1997,26(5):1209-1215.
86 Ijichi M, Takayama T, Matsumura M, et al. alpha-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study[J]. Hepatology, 2002,35(4):853-860.
87 Sell S, Longley MA, Boulter J. Lack of correlation of methylation and alphafetoprotein and albumin gene expression during liver growth, in hepatocellular carcinomas, and during hepatocarcinogenesis[J]. Tumour Biol, 1985,6(2):133-143.
88 Kedda MA, Kew MC, Skelton M, et al. Non-specificity of messenger RNA ofalpha-fetoprotein in peripheral blood in detecting early spread of hepatocellular carcinoma in black Africans[J]. J Gastroenterol Hepatol, 1998,13(9):885-891.
89 Yao F, Guo JM, Xu CF, et al. Detecting AFP mRNA in peripheral blood of the patients with hepatocellular carcinoma, liver cirrhosis and hepatitis[J]. Clin Chim Acta, 2005,361(1-2):119-127.
90 Witzigmann H, Geissler F, Benedix F, et al. Prospective evaluation of circulating hepatocytes by alpha-fetoprotein messenger RNA in patients with hepatocellular carcinoma[J]. Surgery, 2002,131(1):34-43.
91吴晓凤林芷英等.外周血甲胎蛋白mRNA定量与裸鼠肝癌术后复发转移的关系[J].中华肝脏病杂志, 2002,10(3): 189-192.
92 Marubashi S, Dono K, Sugita Y, et al. Alpha-fetoprotein mRNA detection in peripheral blood for prediction of hepatocellular carcinoma recurrence after liver transplantation[J]. Transplant Proc, 2006,38(10):3640-3642.
93 Marubashi S, Dono K, Nagano H, et al. Detection of AFP mRNA-expressing cells in the peripheral blood for prediction of HCC recurrence after living donor liver transplantation[J]. Transpl Int, 2007,20(7):576-582.
94 Minata M, Nishida N, Komeda T, et al. Postoperative detection of alpha-fetoprotein mRNA in blood as a predictor for metastatic recurrence of hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2001,16(4):445-451.
95 Iavarone M, Lampertico P, Ronchi G, et al. A prospective study of blood alpha-fetoprotein messenger RNA as a predictor of hepatocellular carcinoma in patients with cirrhosis[J]. J Viral Hepat, 2003,10(6):423-426.
1. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends[J]. Gastroenterology, 2004,127(5 Suppl 1):S5-S16.
2.陈建国,宋新明.中国肝癌发病水平的估算及分析[J].中国肿瘤, 2005,14(1): 28-31.
3.张思维,李连弟,鲁凤珠,等.中国1990～1992年原发性肝癌死亡调查分析[J].中华肿瘤杂志, 1999,21(4): 245-249.
4.丛文铭,吴孟超,王一,等.肝脏肿瘤3160例临床病理研究[J].中华病理学杂志, 1997,26(2): 70-73.
5. Lai EC, Lau WY. The continuing challenge of hepatic cancer in Asia[J]. Surgeon, 2005,3(3):210-215
6. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2004,130(7):417-422
7. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan[J]. JAMA, 1996,276(11):906-908
8. Chang MH, Shau WY, Chen CJ, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls[J]. JAMA, 2000,284(23):3040-3042
9. Poon RT, Fan ST, Ng IO, et al. Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal[J]. Ann Surg, 2000,231(4):544-551
10. Healey JE Jr, Schroy PC. Anatomy of the biliary ducts within the human liver: analysis of the prevailing pattern of branchings and the major variations of the biliary ducts[J]. Arch Surg, 1953,66:599-616.
11. Healey JE. Clinical anatomic aspects of radical hepatic surgery[J]. J Int Coll Surg, 1954,22:542-550.
12. Couinaud C,Le foi ed.「TiEtudes Anatomiques et Chirurgicales,Masson,Paris, 1957.
13. Couinaud C. Anatomy of the Liver Revisited Ch 4. Anatomy of the Dorsal Sector of the Liver. New considerations on liver anatomy[A]. Paris: Pers Ed, 1989. 26-39.
14. Filipponi F, Romagnoli P, Mosca F, et al. The dorsal sector of human liver: embryological, anatomical and clinical relevance[J]. Hepatogastroenterology, 2000,47(36):1726-1731
15.刘允怡,余俊豪.肝段为本的肝切除手术[J].中华普通外科杂志, 2003,18(2):123-125.
16.邢雪.肝静脉外科[M]. 1版.北京:人民卫生出版社,2005. 95-96.
17.林贵.肝肿瘤微血管结构和血供[J].中华放射学杂志, 1985,19: 257-260.
18. Ishida H, Iwama T, Yoshinaga K, et al. Bromodeoxyuridine uptake by early liver metastases in rats: a comparison of the hepatic artery and portal vein infusion routes[J]. Surg Today, 1998,28(8):822-829
19. Taniguchi H, Daidoh T, Shioaki Y, et al. Blood supply and drug delivery to primary and secondary human liver cancers studied with in vivo bromodeoxyuridine labeling[J]. Cancer, 1993,71(1):50-55
20. Toyosaka A, Okamoto E, Mitsunobu M, et al. Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as an efferent vessel[J]. Am J Gastroenterol, 1996,91(8):1610-1615.
21. Toyosaka A, Okamoto E, Mitsunobu M, et al. Pathologic and radiographic studies of intrahepatic metastasis in hepatocellular carcinoma; the role of efferent vessels[J]. HPB Surg, 1996,10(2):97-103; discussion 103-104.
22.陈孝平,裘法祖,吴在德,等.肝细胞癌门静脉癌栓形成的分子生物学机制研究[J].中华实验外科杂志, 2005,22(9): 1056-1059.
23.王晓颖,樊嘉,周俭,等. CCR1趋化因子受体在人肝癌组织中表达及其临床意义[J].中华肝胆外科杂志, 2006,12(2): 101-104.
24. Lu P, Nakamoto Y, Nemoto-Sasaki Y, et al. Potential interaction between CCR1 and its ligand, CCL3, induced by endogenously produced interleukin-1 in human hepatomas[J]. Am J Pathol, 2003,162(4):1249-1258.
25.安一明,刘倩,陈少华,等.血液流变性改变对肝癌门静脉癌栓形成的影响[J].微循环学杂志, 1996,6(4): 36-37.
26. Herber S, Pitton M, Monch C, et al. Transarterial chemoembolization (TACE) of the hepatocellular carcinoma (HCC) in patients with portal vein thrombosis--experiences[J]. Zentralbl Chir, 2007,132(4):306-315
27. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials[J]. Hepatology, 1999,29(1):62-67
28. Takizawa D, Kakizaki S, Sohara N, et al. Hepatocellular carcinoma with portal veintumor thrombosis: clinical characteristics, prognosis, and patient survival analysis[J]. Dig Dis Sci, 2007,52(11):3290-3295
29. Sumie S, Kuromatsu R, Okuda K, et al. Microvascular Invasion in Patients with Hepatocellular Carcinoma and Its Predictable Clinicopathological Factors[J]. Ann Surg Oncol, 2008,15(5):1375-1382
30. Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey[J]. Cancer, 2004,101(4):796-802.
31.吴孟超,陈汉,沈锋.原发性肝癌的外科治疗--附5524例报告[J].中华外科杂志, 2001,39(1): 25-28.
32. Lee HH, Joh JW, Park JH, et al. Microvascular tumor embolism: independent prognostic factor after liver transplantation in hepatocellular carcinoma[J]. Transplant Proc, 2005,37(2):1251-1253
33. Chau GY, Lui WY, Wu CW. Spectrum and significance of microscopic vascular invasion in hepatocellular carcinoma[J]. Surg Oncol Clin N Am, 2003,12(1):25-34
34.石明,张昌卿,冯凯涛,等.肝细胞癌周围微小转移分布的研究[J].中华肿瘤杂志, 2002,24(3): 257-260.
35.程树群,吴孟超,陈汉,等.肝癌门静脉癌栓分型的影像学意义[J].中华普通外科杂志, 2004,19(4): 200-201.
36.樊嘉,汤钊猷,吴志全,等.门静脉微癌栓和肉眼癌栓对肝癌患者术后生存的影响[J].中华外科杂志, 2005,43(7): 433-435.
37. Lau H, Fan ST, Ng IO, et al. Long term prognosis after hepatectomy for hepatocellular carcinoma: a survival analysis of 204 consecutive patients[J]. Cancer, 1998,83(11):2302-2311
38. Minagawa M, Makuuchi M, Takayama T, et al. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus[J]. Ann Surg, 2001,233(3):379-384
39. Zhou XD, Tang ZY, Yang BH, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma[J]. Cancer, 2001,91(8):1479-1486
40. Shimozawa N, Hanazaki K. Longterm prognosis after hepatic resection for small hepatocellular carcinoma[J]. J Am Coll Surg, 2004,198(3):356-365
41. Zhou XD, Tang ZY, Ma ZC, et al. Surgery for large primary liver cancer more than 10 cm in diameter[J]. J Cancer Res Clin Oncol, 2003,129(9):543-548
42. Nagano Y, Tanaka K, Togo S, et al. Efficacy of hepatic resection for hepatocellular carcinomas larger than 10 cm[J]. World J Surg, 2005,29(1):66-71.
43. Chen XP, Qiu FZ, Wu ZD, et al. Long-term outcome of resection of large hepatocellular carcinoma[J]. Br J Surg, 2006,93(5):600-606
44. Shirabe K, Shimada M, Gion T, et al. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume[J]. J Am Coll Surg, 1999,188(3):304-309
45. Cherrick GR, Stein SW, Leevy CM, et al. Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction[J]. J Clin Invest, 1960,39:592-600.
46. Imamura H, Sano K, Sugawara Y, et al. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test[J]. J Hepatobiliary Pancreat Surg, 2005,12(1):16-22.
47. Fan ST. Methods and related drawbacks in the estimation of surgical risks in cirrhotic patients undergoing hepatectomy[J]. Hepatogastroenterology, 2002,49(43):17-20.
48. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg, 1973,60(8):646-649
49. Van Thiel DH, Wright HI, Fagiuoli S, et al. Preoperative evaluation of a patient for hepatic surgery[J]. J Surg Oncol Suppl, 1993,3:49-51.
50. Lam CM, Fan ST, Lo CM, et al. Major hepatectomy for hepatocellular carcinoma in patients with an unsatisfactory indocyanine green clearance test[J]. Br J Surg, 1999,86(8):1012-1017
51.戴朝六.肝脏储备功能的评估[J].中国实用外科杂志, 2005,25(12): 708-710.
52. Ochiai T, Sonoyama T, Kikuchi S, et al. Anatomic wide hepatectomy for treatment of hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2007,133(8):563-569
53. Hasegawa K, Kokudo N, Imamura H, et al. Prognostic impact of anatomic resection for hepatocellular carcinoma[J]. Ann Surg, 2005,242(2):252-259
54. Ziparo V, Balducci G, Lucandri G, et al. Indications and results of resection for hepatocellular carcinoma[J]. Eur J Surg Oncol, 2002,28(7):723-728.
55. Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years[J]. Ann Surg, 2001,234(1):63-70.
56. Hanazaki K, Kajikawa S, Shimozawa N, et al. Perioperative blood transfusion and survival following curative hepatic resection for hepatocellular carcinoma[J]. Hepatogastroenterology, 2005,52(62):524-529
57. Yeh CN, Lee WC, Jeng LB, et al. Hepatic resection for hepatocellular carcinoma in Taiwan[J]. Eur J Surg Oncol, 2002,28(6):652-656
58. Kwon AH, Matsui Y, Kamiyama Y. Perioperative blood transfusion in hepatocellular carcinomas: influence of immunologic profile and recurrence free survival[J]. Cancer, 2001,91(4):771-778
59. Uchida H, Tanaka H, Kitoh Y, et al. Mechanisms of immunomodulation induced by blood transfusion: identification of humoral factors[J]. Transplant Proc, 2000,32(2):255-256
60. Wong IH, Yeo W, Leung T,et al. Circulating tumor cell mRNAs in peripheral blood from hepatocellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: a quantitative evaluation[J]. Cancer Lett, 2001,167(2):183-191.
61. Cho YB, Lee KU, Lee HW, et al. Anatomic versus non-anatomic resection for small single hepatocellular carcinomas[J]. Hepatogastroenterology, 2007,54(78):1766-1769
62. Castaing D, Garden OJ, Bismuth H. Segmental liver resection using ultrasound-guided selective portal venous occlusion[J]. Ann Surg, 1989,210:20-23.
63. Guido Torzilli, MD, FPCR, Tadatoshi Takayama, MD, PhD, Ai-Min Hui, MD, PhD,et al. A New Technical Aspect of Ultrasound-guided Liver Surgery[J]. THE AMERICAN JOURNAL OF SURGERY, 1999,178(9):341-343.
64. Blumgart LH, Fong Y eds. Segment-oriented anatomical liver resection. In: Scheele J, Stangl R, editor. Surgery of the liver and biliary tract. 2000. London:W.B. Saunders. 1743-1763.
65.窦科峰,王德盛.肝脏手术中止血方法的新进展[J].中国实用外科杂志, 2005,25(1): 62-64.
66.苏永杰,董家鸿,李海林,等. TissueLink与钳夹法在肝癌切除术中的应用比较[J].中国现代普通外科进展, 2008,11(1): 7-9.
67. Sakamoto Y, Yamamoto J, Kokudo N, et al. Bloodless liver resection using the monopolar floating ball plus ligasure diathermy: preliminary results of 16 liver resections[J]. World J Surg, 2004,28(2):166-172
68. Yu-Chung Chang, M.D, Ph.D, Naofumi Nagasue, M.D Ph.D, Xi-Zhang Lin, M.D.et al. Easier hepatic resections with a straight needle[J]. The American Journal of Surgery, 2001,182:260-264.
2陈建国,宋新明.中国肝癌发病水平的估算及分析[J].中国肿瘤, 2005,14(1): 28-31.
3张思维,李连弟,鲁凤珠,等.中国1990～1992年原发性肝癌死亡调查分析[J].中华肿瘤杂志, 1999,21(4): 245-249.
4丛文铭,吴孟超,王一,等.肝脏肿瘤3160例临床病理研究[J].中华病理学杂志, 1997,26(2): 70-73.
5 Healey JE Jr, Schroy PC. Anatomy of the biliary ducts within the human liver: analysis of the prevailing pattern of branchings and the major variations of the biliary ducts[J]. Arch Surg, 1953,66:599-616.
6 Healey JE. Clinical anatomic aspects of radical hepatic surgery[J]. J Int Coll Surg, 1954,22:542-550.
7 Couinaud C,Le Foie. Etudes Anatomiques et Chirurgicales[A]. Paris:Masson&Cie, 1957, 284-289.
8 Couinaud C. Surgical anatomy of the liver revisited ch 4. anatomy of the dorsal sector of the liver. New considerations on liver anatomy[A]. Paris: Pers Ed, 1989. 26-39.
9 Cahill BA, Braccia D. Current treatment for hepatocellular carcinoma[J]. Clin J Oncol Nurs, 2004,8(4):393-9.
10 Yanaga K. Current status of hepatic resection for hepatocellular carcinoma[J]. J Gastroenterol, 2004,39(10):919-926.
11 Poon RT, Fan ST, Ng IO, et al. Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal[J]. Ann Surg, 2000,231(4):544-551.
12吴孟超.原发性肝癌外科综合治疗的现状和展望[J].中华外科杂志, 2004,42(1): 13-15.
13 Hasegawa K, Kokudo N, Imamura H, et al. Prognostic impact of anatomic resection for hepatocellular carcinoma[J]. Ann Surg, 2005,242(2):252-259.
14 Suh KS. Systematic hepatectomy for small hepatocellular carcinoma in Korea[J]. J Hepatobiliary Pancreat Surg, 2005,12(5):365-370.
15 Capussotti L, Muratore A, Amisano M, et al. Liver resection for hepatocellularcarcinoma on cirrhosis: analysis of mortality, morbidity and survival--a European single center experience[J]. Eur J Surg Oncol, 2005,31(9):986-993.
16 Shi M, Zhang CQ, Zhang YQ, et al. Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin[J]. World J Surg, 2004,28(4):376-381.
17 Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey[J]. Cancer, 2004,101(4):796-802.
18 Poon RT, Fan ST, Ng IO, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma[J]. Cancer, 2000,89(3):500-507.
19 Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy[J]. J Hepatol, 2003,38(2):200-207.
20 Kamiyama T, Takahashi M, Nakagawa T, et al. AFP mRNA detected in bone marrow by real-time quantitative RT-PCR analysis predicts survival and recurrence after curative hepatectomy for hepatocellular carcinoma[J]. Ann Surg, 2006,244(3): 451-463.
21 Wong IH, Yeo W, Leung T, et al. Circulating tumor cell mRNAs in peripheral blood from hepatocellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: a quantitative evaluation[J]. Caner Lett, 2001,167(2):183-191.
22 Wang YL, Li G, Wu D, et al. Analysis of alpha-fetoprotein mRNA level on the tumor cell hematogenous spread of patients with hepatocellular carcinoma undergoing orthotopic liver transplantation[J]. Transplant Proc, 2007,39(1):166-168.
23蒋知俭.医学统计学[M].第1版.北京:人民卫生出版社,1997. 572.
24 Liau KH, Blumgart LH, DeMatteo RP. Segment-oriented approach to liver resection[J]. Surg Clin North Am, 2004,84(2):543-561.
25 Billingsley KG, Jarnagin WR, Fong Y, et al. Segment-oriented hepatic resection in the management of malignant neoplasms of the liver[J]. J Am Coll Surg, 1998, 187(5):471-481.
26 Sobin LH, Wittekind C, eds, ed. International Union Against Cancer (IUAC).TNM classification of malignant tumors.6th ed[M]. New York:Wiley-Liss,2002. 81-83.
27彭淑牖,冯雪冬,刘颖斌,等.肝尾状叶原发性肝细胞肝癌的外科治疗[J].中华外科杂志, 2005,43(1): 49-52.
28黄志强,周宁新,黄晓强,等.尾状叶外科———肝外科的最后领域[J].消化外科, 2004,3(1): 1-17.
29 Imamura H, Sano K, Sugawara Y, et al. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test[J]. J Hepatobiliary Pancreat Surg, 2005,12(1):16-22.
30 Fan ST. Methods and related drawbacks in the estimation of surgical risks in cirrhotic patients undergoing hepatectomy[J]. Hepatogastroenterology, 2002,49(43):17-20.
31 Van Thiel DH, Wright HI, Fagiuoli S, et al. Preoperative evaluation of a patient for hepatic surgery[J]. J Surg Oncol Suppl, 1993,3:49-51.
32 Lam CM, Fan ST, Lo CM, et al. Major hepatectomy for hepatocellular carcinoma in patients with an unsatisfactory indocyanine green clearance test[J]. Br J Surg, 1999,86(8):1012-1017.
33 Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg, 1973,60(8):646-649.
34戴朝六.肝脏储备功能的评估[J].中国实用外科杂志, 2005,25(12): 708-710.
35 Hanazaki K, Matsushita A, Nakagawa K, et al. Risk factors of long-term survival and recurrence after curative resection of hepatocellular carcinoma[J]. Hepatogastroenterology, 2005,52(62):552-557.
36 Hanazaki K, Kajikawa S, Shimozawa N, et al. Perioperative blood transfusion and survival following curative hepatic resection for hepatocellular carcinoma[J]. Hepatogastroenterology, 2005,52(62):524-529.
37袁爱军黄兴耀.肝癌切除术中的外科切缘(附544例分析)[J].中国实用外科杂志, 2001,21(4): 220-221.
38吴福生,赵文和,梁廷波,等.影响3cm以下小肝癌患者术后生存因素的观察[J].中华外科杂志, 2005,43(9): 579-583.
39周学平,杨广顺,丛文铭,等.原发性肝癌瘤周肝组织内微转移的回顾性与前瞻性研究[J].中华肝胆外科杂志, 2005,11(8): 510-514.
40徐立,石明,张亚奇,等.肝细胞癌手术切缘对患者术后复发与生存的影响[J].中华肿瘤杂志, 2006,28(1): 47-49.
41李升平,张昌卿,冯凯涛,等.肝癌亚临床转移灶及临床病理学意义的研究[J].中国肿瘤临床, 2002,29(2): 77-81.
42 Kosuge T, Makuuchi M, Takayama T, et al. Long-term results after resection of hepatocellular carcinoma: experience of 480 cases[J]. Hepatogastroenterology, 1993,40(4):328-332.
43 Wu CC, Hwang CJ, Yang MD, et al. Preliminary results of hepatic resection for centrally located large hepatocellular carcinoma[J]. Aust N Z J Surg, 1993,63(7):525-529.
44 Ochiai T, Takayama T, Inoue K, et al. Hepatic resection with and without surgical margins for hepatocellular carcinoma in patients with impaired liver function[J]. Hepatogastroenterology, 1999,46(27):1885-1889.
45 Shimada M, Gion T, Hamatsu T, et al. Evaluation of major hepatic resection for small hepatocellular carcinoma[J]. Hepatogastroenterology, 1999,46(25):401-406.
46 Cho YB, Lee KU, Lee HW, et al. Anatomic versus non-anatomic resection for small single hepatocellular carcinomas[J]. Hepatogastroenterology, 2007,54(78):1766-1769.
47 Ochiai T, Sonoyama T, Kikuchi S, et al. Anatomic wide hepatectomy for treatment of hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2007,133(8):563-569.
48 Yamashita Y, Taketomi A, Itoh S, et al. Longterm favorable results of limited hepatic resections for patients with hepatocellular carcinoma: 20 years of experience[J]. J Am Coll Surg, 2007,205(1):19-26.
49林贵.肝肿瘤微血管结构和血供[J].中华放射学杂志, 1985,19: 257-260.
50 Ishida H, Iwama T, Yoshinaga K, et al. Bromodeoxyuridine uptake by early liver metastases in rats: a comparison of the hepatic artery and portal vein infusion routes[J]. Surg Today, 1998,28(8):822-829.
51 Taniguchi H, Daidoh T, Shioaki Y, et al. Blood supply and drug delivery to primary and secondary human liver cancers studied with in vivo bromodeoxyuridine labeling[J]. Cancer, 1993,71(1):50-55.
52 Toyosaka A, Okamoto E, Mitsunobu M, et al. Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as an efferent vessel[J]. Am J Gastroenterol, 1996,91(8):1610-1615.
53 Toyosaka A, Okamoto E, Mitsunobu M, et al. Pathologic and radiographic studies ofintrahepatic metastasis in hepatocellular carcinoma; the role of efferent vessels[J]. HPB Surg, 1996,10(2):97-103; discussion 103-104.
54 Takizawa D, Kakizaki S, Sohara N, et al. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis[J]. Dig Dis Sci, 2007,52(11):3290-3295.
55 Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials[J]. Hepatology, 1999,29(1):62-67.
56 Sumie S, Kuromatsu R, Okuda K, et al. Microvascular Invasion in Patients with Hepatocellular Carcinoma and Its Predictable Clinicopathological Factors[J]. Ann Surg Oncol, 2008.
57吴孟超,陈汉,沈锋.原发性肝癌的外科治疗--附5524例报告[J].中华外科杂志, 2001,39(1): 25-28.
58 Lee HH, Joh JW, Park JH, et al. Microvascular tumor embolism: independent prognostic factor after liver transplantation in hepatocellular carcinoma[J]. Transplant Proc, 2005,37(2):1251-1253.
59 Chau GY, Lui WY, Wu CW. Spectrum and significance of microscopic vascular invasion in hepatocellular carcinoma[J]. Surg Oncol Clin N Am, 2003,12(1):25-34.
60樊嘉,汤钊猷,吴志全,等.门静脉微癌栓和肉眼癌栓对肝癌患者术后生存的影响[J].中华外科杂志, 2005,43(7): 433-435.
61刘允怡,余俊豪.肝段为本的肝切除手术[J].中华普通外科杂志, 2003,18(2): 123-125.
62 Wong IH, Yeo W, Leung T,et al. Circulating tumor cell mRNAs in peripheral blood from hepatocellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: a quantitative evaluation[J]. Cancer Lett, 2001,167(2):183-191.
63 Farges O, Regimbeau JM, Belghiti J. Aggressive management of recurrence following surgical resection of hepatocellular carcinoma[J]. Hepatogastroenterology, 1998,45 Suppl 3:1275-1280.
64黎乐群,彭涛,林进令,等.复发性肝细胞癌的细胞克隆来源及其与复发时间的关系[J].中华肝胆外科杂志, 1999,5(1): 11-13.
65 Sirivatanauksorn Y, Sirivatanauksorn V, Bhattacharya S, et al. Genomic heterogeneityin synchronous hepatocellular carcinomas[J]. Gut, 1999,45(5):761-765.
66 Hanazaki K, Kajikawa S, Koide N, et al. Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis[J]. Am J Gastroenterol, 2001,96(4):1243-1250.
67吴育连,苏昆仑,董鑫,等.肝癌切除术后早/晚期复发的危险因素与治疗[J].中华肝胆外科杂志, 2006,12(6): 370-373.
68 Grazi GL, Cescon M, Ravaioli M, et al. Liver resection for hepatocellular carcinoma in cirrhotics and noncirrhotics. Evaluation of clinicopathologic features and comparison of risk factors for long-term survival and tumour recurrence in a single centre[J]. Aliment Pharmacol Ther, 2003,17 Suppl 2:119-129.
69周信达,汤钊猷,杨秉辉,等. 1000例小肝癌手术切除经验[J].中国实用外科杂志, 2001,21(1): 41-44.
70 Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma[J]. Liver Transpl, 2005,11(9):1086-1092.
71 Hu RH, Lee PH, Chang YC, et al. Prognostic factors for hepatocellular carcinoma < or = 3 cm in diameter[J]. Hepatogastroenterology, 2003,50(54):2043-2048.
72 Nakashima Y, Nakashima O, Tanaka M, et al. Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type[J]. Hepatol Res, 2003,26(2):142-147.
73吴福生,赵文和,梁廷波,等.影响3 cm以下小肝癌患者术后生存因素的观察[J].中华外科杂志, 2005,43(9): 579-583.
74 Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years[J]. Ann Surg, 2001,234(1):63-70.
75 Zhou XD. Recurrence and metastasis of hepatocellular carcinoma: progress and prospects[J]. Hepatobiliary Pancreat Dis Int, 2002,1(1):35-41.
76 Yeh CN, Lee WC, Jeng LB, et al. Hepatic resection for hepatocellular carcinoma in Taiwan[J]. Eur J Surg Oncol, 2002,28(6):652-656.
77 Makino Y, Yamanoi A, Kimoto T, et al. The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellularcarcinoma[J]. Am J Gastroenterol, 2000,95(5):1294-1300.
78 Kwon AH, Matsui Y, Kamiyama Y. Perioperative blood transfusion in hepatocellular carcinomas: influence of immunologic profile and recurrence free survival[J]. Cancer, 2001,91(4):771-778.
79 Sabalic S, Kovacevic D, Glavic Z, et al. The immunomodulation effect of allogenic blood transfusion in colorectal cancer--a new approach[J]. Coll Antropol, 2006,30(4):885-893.
80 Uchida H, Tanaka H, Kitoh Y, et al. Mechanisms of immunomodulation induced by blood transfusion: identification of humoral factors[J]. Transplant Proc, 2000,32(2):255-256.
81苏永杰,董家鸿,李海林,等. TissueLink与钳夹法在肝癌切除术中的应用比较[J].中国现代普通外科进展, 2008,11(1): 7-9.
82 Sakamoto Y, Yamamoto J, Kokudo N, et al. Bloodless liver resection using the monopolar floating ball plus ligasure diathermy: preliminary results of 16 liver resections[J]. World J Surg, 2004,28(2):166-172.
83 Hermanek P,Henson D,Hutter R,SobinL,editors. International Union Against Cancer.TNM Supplement 1993. A commentary on uniform use[M]. Berlin: Springer, 1993.
84 Page DL, Anderson TJ, Carter BA. Minimal solid tumor involvement of regional and distant sites: when is a metastasis not a metastasis?[J]. Cancer, 1999,86(12):2589-2592.
85 Lindsay CK, Sinha CC, Thorgeirsson UP. Morphological study of vascular dissemination in a metastatic hepatocellular carcinoma model in the monkey[J]. Hepatology, 1997,26(5):1209-1215.
86 Ijichi M, Takayama T, Matsumura M, et al. alpha-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study[J]. Hepatology, 2002,35(4):853-860.
87 Sell S, Longley MA, Boulter J. Lack of correlation of methylation and alphafetoprotein and albumin gene expression during liver growth, in hepatocellular carcinomas, and during hepatocarcinogenesis[J]. Tumour Biol, 1985,6(2):133-143.
88 Kedda MA, Kew MC, Skelton M, et al. Non-specificity of messenger RNA ofalpha-fetoprotein in peripheral blood in detecting early spread of hepatocellular carcinoma in black Africans[J]. J Gastroenterol Hepatol, 1998,13(9):885-891.
89 Yao F, Guo JM, Xu CF, et al. Detecting AFP mRNA in peripheral blood of the patients with hepatocellular carcinoma, liver cirrhosis and hepatitis[J]. Clin Chim Acta, 2005,361(1-2):119-127.
90 Witzigmann H, Geissler F, Benedix F, et al. Prospective evaluation of circulating hepatocytes by alpha-fetoprotein messenger RNA in patients with hepatocellular carcinoma[J]. Surgery, 2002,131(1):34-43.
91吴晓凤林芷英等.外周血甲胎蛋白mRNA定量与裸鼠肝癌术后复发转移的关系[J].中华肝脏病杂志, 2002,10(3): 189-192.
92 Marubashi S, Dono K, Sugita Y, et al. Alpha-fetoprotein mRNA detection in peripheral blood for prediction of hepatocellular carcinoma recurrence after liver transplantation[J]. Transplant Proc, 2006,38(10):3640-3642.
93 Marubashi S, Dono K, Nagano H, et al. Detection of AFP mRNA-expressing cells in the peripheral blood for prediction of HCC recurrence after living donor liver transplantation[J]. Transpl Int, 2007,20(7):576-582.
94 Minata M, Nishida N, Komeda T, et al. Postoperative detection of alpha-fetoprotein mRNA in blood as a predictor for metastatic recurrence of hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2001,16(4):445-451.
95 Iavarone M, Lampertico P, Ronchi G, et al. A prospective study of blood alpha-fetoprotein messenger RNA as a predictor of hepatocellular carcinoma in patients with cirrhosis[J]. J Viral Hepat, 2003,10(6):423-426.
1. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends[J]. Gastroenterology, 2004,127(5 Suppl 1):S5-S16.
2.陈建国,宋新明.中国肝癌发病水平的估算及分析[J].中国肿瘤, 2005,14(1): 28-31.
3.张思维,李连弟,鲁凤珠,等.中国1990～1992年原发性肝癌死亡调查分析[J].中华肿瘤杂志, 1999,21(4): 245-249.
4.丛文铭,吴孟超,王一,等.肝脏肿瘤3160例临床病理研究[J].中华病理学杂志, 1997,26(2): 70-73.
5. Lai EC, Lau WY. The continuing challenge of hepatic cancer in Asia[J]. Surgeon, 2005,3(3):210-215
6. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2004,130(7):417-422
7. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan[J]. JAMA, 1996,276(11):906-908
8. Chang MH, Shau WY, Chen CJ, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls[J]. JAMA, 2000,284(23):3040-3042
9. Poon RT, Fan ST, Ng IO, et al. Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal[J]. Ann Surg, 2000,231(4):544-551
10. Healey JE Jr, Schroy PC. Anatomy of the biliary ducts within the human liver: analysis of the prevailing pattern of branchings and the major variations of the biliary ducts[J]. Arch Surg, 1953,66:599-616.
11. Healey JE. Clinical anatomic aspects of radical hepatic surgery[J]. J Int Coll Surg, 1954,22:542-550.
12. Couinaud C,Le foi ed.「TiEtudes Anatomiques et Chirurgicales,Masson,Paris, 1957.
13. Couinaud C. Anatomy of the Liver Revisited Ch 4. Anatomy of the Dorsal Sector of the Liver. New considerations on liver anatomy[A]. Paris: Pers Ed, 1989. 26-39.
14. Filipponi F, Romagnoli P, Mosca F, et al. The dorsal sector of human liver: embryological, anatomical and clinical relevance[J]. Hepatogastroenterology, 2000,47(36):1726-1731
15.刘允怡,余俊豪.肝段为本的肝切除手术[J].中华普通外科杂志, 2003,18(2):123-125.
16.邢雪.肝静脉外科[M]. 1版.北京:人民卫生出版社,2005. 95-96.
17.林贵.肝肿瘤微血管结构和血供[J].中华放射学杂志, 1985,19: 257-260.
18. Ishida H, Iwama T, Yoshinaga K, et al. Bromodeoxyuridine uptake by early liver metastases in rats: a comparison of the hepatic artery and portal vein infusion routes[J]. Surg Today, 1998,28(8):822-829
19. Taniguchi H, Daidoh T, Shioaki Y, et al. Blood supply and drug delivery to primary and secondary human liver cancers studied with in vivo bromodeoxyuridine labeling[J]. Cancer, 1993,71(1):50-55
20. Toyosaka A, Okamoto E, Mitsunobu M, et al. Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as an efferent vessel[J]. Am J Gastroenterol, 1996,91(8):1610-1615.
21. Toyosaka A, Okamoto E, Mitsunobu M, et al. Pathologic and radiographic studies of intrahepatic metastasis in hepatocellular carcinoma; the role of efferent vessels[J]. HPB Surg, 1996,10(2):97-103; discussion 103-104.
22.陈孝平,裘法祖,吴在德,等.肝细胞癌门静脉癌栓形成的分子生物学机制研究[J].中华实验外科杂志, 2005,22(9): 1056-1059.
23.王晓颖,樊嘉,周俭,等. CCR1趋化因子受体在人肝癌组织中表达及其临床意义[J].中华肝胆外科杂志, 2006,12(2): 101-104.
24. Lu P, Nakamoto Y, Nemoto-Sasaki Y, et al. Potential interaction between CCR1 and its ligand, CCL3, induced by endogenously produced interleukin-1 in human hepatomas[J]. Am J Pathol, 2003,162(4):1249-1258.
25.安一明,刘倩,陈少华,等.血液流变性改变对肝癌门静脉癌栓形成的影响[J].微循环学杂志, 1996,6(4): 36-37.
26. Herber S, Pitton M, Monch C, et al. Transarterial chemoembolization (TACE) of the hepatocellular carcinoma (HCC) in patients with portal vein thrombosis--experiences[J]. Zentralbl Chir, 2007,132(4):306-315
27. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials[J]. Hepatology, 1999,29(1):62-67
28. Takizawa D, Kakizaki S, Sohara N, et al. Hepatocellular carcinoma with portal veintumor thrombosis: clinical characteristics, prognosis, and patient survival analysis[J]. Dig Dis Sci, 2007,52(11):3290-3295
29. Sumie S, Kuromatsu R, Okuda K, et al. Microvascular Invasion in Patients with Hepatocellular Carcinoma and Its Predictable Clinicopathological Factors[J]. Ann Surg Oncol, 2008,15(5):1375-1382
30. Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey[J]. Cancer, 2004,101(4):796-802.
31.吴孟超,陈汉,沈锋.原发性肝癌的外科治疗--附5524例报告[J].中华外科杂志, 2001,39(1): 25-28.
32. Lee HH, Joh JW, Park JH, et al. Microvascular tumor embolism: independent prognostic factor after liver transplantation in hepatocellular carcinoma[J]. Transplant Proc, 2005,37(2):1251-1253
33. Chau GY, Lui WY, Wu CW. Spectrum and significance of microscopic vascular invasion in hepatocellular carcinoma[J]. Surg Oncol Clin N Am, 2003,12(1):25-34
34.石明,张昌卿,冯凯涛,等.肝细胞癌周围微小转移分布的研究[J].中华肿瘤杂志, 2002,24(3): 257-260.
35.程树群,吴孟超,陈汉,等.肝癌门静脉癌栓分型的影像学意义[J].中华普通外科杂志, 2004,19(4): 200-201.
36.樊嘉,汤钊猷,吴志全,等.门静脉微癌栓和肉眼癌栓对肝癌患者术后生存的影响[J].中华外科杂志, 2005,43(7): 433-435.
37. Lau H, Fan ST, Ng IO, et al. Long term prognosis after hepatectomy for hepatocellular carcinoma: a survival analysis of 204 consecutive patients[J]. Cancer, 1998,83(11):2302-2311
38. Minagawa M, Makuuchi M, Takayama T, et al. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus[J]. Ann Surg, 2001,233(3):379-384
39. Zhou XD, Tang ZY, Yang BH, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma[J]. Cancer, 2001,91(8):1479-1486
40. Shimozawa N, Hanazaki K. Longterm prognosis after hepatic resection for small hepatocellular carcinoma[J]. J Am Coll Surg, 2004,198(3):356-365
41. Zhou XD, Tang ZY, Ma ZC, et al. Surgery for large primary liver cancer more than 10 cm in diameter[J]. J Cancer Res Clin Oncol, 2003,129(9):543-548
42. Nagano Y, Tanaka K, Togo S, et al. Efficacy of hepatic resection for hepatocellular carcinomas larger than 10 cm[J]. World J Surg, 2005,29(1):66-71.
43. Chen XP, Qiu FZ, Wu ZD, et al. Long-term outcome of resection of large hepatocellular carcinoma[J]. Br J Surg, 2006,93(5):600-606
44. Shirabe K, Shimada M, Gion T, et al. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume[J]. J Am Coll Surg, 1999,188(3):304-309
45. Cherrick GR, Stein SW, Leevy CM, et al. Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction[J]. J Clin Invest, 1960,39:592-600.
46. Imamura H, Sano K, Sugawara Y, et al. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test[J]. J Hepatobiliary Pancreat Surg, 2005,12(1):16-22.
47. Fan ST. Methods and related drawbacks in the estimation of surgical risks in cirrhotic patients undergoing hepatectomy[J]. Hepatogastroenterology, 2002,49(43):17-20.
48. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg, 1973,60(8):646-649
49. Van Thiel DH, Wright HI, Fagiuoli S, et al. Preoperative evaluation of a patient for hepatic surgery[J]. J Surg Oncol Suppl, 1993,3:49-51.
50. Lam CM, Fan ST, Lo CM, et al. Major hepatectomy for hepatocellular carcinoma in patients with an unsatisfactory indocyanine green clearance test[J]. Br J Surg, 1999,86(8):1012-1017
51.戴朝六.肝脏储备功能的评估[J].中国实用外科杂志, 2005,25(12): 708-710.
52. Ochiai T, Sonoyama T, Kikuchi S, et al. Anatomic wide hepatectomy for treatment of hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2007,133(8):563-569
53. Hasegawa K, Kokudo N, Imamura H, et al. Prognostic impact of anatomic resection for hepatocellular carcinoma[J]. Ann Surg, 2005,242(2):252-259
54. Ziparo V, Balducci G, Lucandri G, et al. Indications and results of resection for hepatocellular carcinoma[J]. Eur J Surg Oncol, 2002,28(7):723-728.
55. Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years[J]. Ann Surg, 2001,234(1):63-70.
56. Hanazaki K, Kajikawa S, Shimozawa N, et al. Perioperative blood transfusion and survival following curative hepatic resection for hepatocellular carcinoma[J]. Hepatogastroenterology, 2005,52(62):524-529
57. Yeh CN, Lee WC, Jeng LB, et al. Hepatic resection for hepatocellular carcinoma in Taiwan[J]. Eur J Surg Oncol, 2002,28(6):652-656
58. Kwon AH, Matsui Y, Kamiyama Y. Perioperative blood transfusion in hepatocellular carcinomas: influence of immunologic profile and recurrence free survival[J]. Cancer, 2001,91(4):771-778
59. Uchida H, Tanaka H, Kitoh Y, et al. Mechanisms of immunomodulation induced by blood transfusion: identification of humoral factors[J]. Transplant Proc, 2000,32(2):255-256
60. Wong IH, Yeo W, Leung T,et al. Circulating tumor cell mRNAs in peripheral blood from hepatocellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: a quantitative evaluation[J]. Cancer Lett, 2001,167(2):183-191.
61. Cho YB, Lee KU, Lee HW, et al. Anatomic versus non-anatomic resection for small single hepatocellular carcinomas[J]. Hepatogastroenterology, 2007,54(78):1766-1769
62. Castaing D, Garden OJ, Bismuth H. Segmental liver resection using ultrasound-guided selective portal venous occlusion[J]. Ann Surg, 1989,210:20-23.
63. Guido Torzilli, MD, FPCR, Tadatoshi Takayama, MD, PhD, Ai-Min Hui, MD, PhD,et al. A New Technical Aspect of Ultrasound-guided Liver Surgery[J]. THE AMERICAN JOURNAL OF SURGERY, 1999,178(9):341-343.
64. Blumgart LH, Fong Y eds. Segment-oriented anatomical liver resection. In: Scheele J, Stangl R, editor. Surgery of the liver and biliary tract. 2000. London:W.B. Saunders. 1743-1763.
65.窦科峰,王德盛.肝脏手术中止血方法的新进展[J].中国实用外科杂志, 2005,25(1): 62-64.
66.苏永杰,董家鸿,李海林,等. TissueLink与钳夹法在肝癌切除术中的应用比较[J].中国现代普通外科进展, 2008,11(1): 7-9.
67. Sakamoto Y, Yamamoto J, Kokudo N, et al. Bloodless liver resection using the monopolar floating ball plus ligasure diathermy: preliminary results of 16 liver resections[J]. World J Surg, 2004,28(2):166-172
68. Yu-Chung Chang, M.D, Ph.D, Naofumi Nagasue, M.D Ph.D, Xi-Zhang Lin, M.D.et al. Easier hepatic resections with a straight needle[J]. The American Journal of Surgery, 2001,182:260-264.